Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Carbonatix Pre-Player Loader

Audio By Carbonatix

CARLSBAD, Calif.--(BUSINESS WIRE)--Mar 5, 2025--

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2024 financial and operating results and to provide a business update.

Interested parties may access the conference call on Monday, March 10, 2025, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through March 17 th, 2025, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 6707203.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, “off-the-shelf,” cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient’s functional activity. Lineage’s neuroscience focused pipeline currently includes: (i) OpRegen ®, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ReSonance™ (ANP1), an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed under a gene editing partnership. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250225709526/en/

CONTACT: Lineage Cell Therapeutics, Inc. IR

Ioana C. Hone

([email protected])

(442) 287-8963Russo Partners – Media Relations

Nic Johnson or David Schull

([email protected])

([email protected])

(212) 845-4242

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH STEM CELLS NEUROLOGY CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Lineage Cell Therapeutics, Inc.

Copyright Business Wire 2025.

PUB: 03/05/2025 08:00 AM/DISC: 03/05/2025 08:00 AM

http://www.businesswire.com/news/home/20250225709526/en

 

Trending Videos

Salem News Channel Today

Sponsored Links

Trending Videos

On Air & Up Next

  • Silicon Valley Insider
    1:00PM - 2:01PM
     
    Keith Koo, with Silicon Valley Insider, provides the latest information on   >>
     
  • The Heart of Innovation
     
    The Heart of Innovation is 60 minutes with life and limb saving potential. Emmy   >>
     
  • Bloomberg Businessweek
    3:00PM - 4:00PM
     
    Get the latest news from the world of business and finance and the interesting   >>
     
  • Money Pulse
    4:00PM - 4:30PM
     
    Host Dynasti Young and Craig Roberts talk to innovative startups and enduring businesses here in the Bay Area.
     
  • California Business Connections
     
    Host Carl Davis Junior talks to the rock starts of Silicon Valley, and offers you engaging interviews and insights.
     

See the Full Program Guide